{"product_id":"hepabig-hepatitis-b-human-immunoglobulin","title":"Hepabig (Hepatitis B Human Immunoglobulin)","description":"Hepabig (Hepatitis B Human Immunoglobulin) – Post-Exposure Protection \u0026amp; Perinatal Prevention\u003cbr\u003e\u003cbr\u003eHepabig is a sterile, ready-to-use human hepatitis B immune globulin (HBIG) solution containing specific antibodies against hepatitis B surface antigen (HBsAg). Sourced from plasma of immune donors, it delivers immediate passive immunity for individuals exposed to hepatitis B virus (HBV) and is essential for post-exposure prophylaxis, perinatal transmission prevention, and protection of unvaccinated or inadequately immunized individuals. This pharmaceutical-grade immunoglobulin is widely used in clinical and public health settings across the Philippines and Southeast Asia to prevent acute HBV infection following exposure.\u003cbr\u003e\u003cbr\u003eWhat is HBIG?\u003cbr\u003e\u003cbr\u003eHepatitis B immunoglobulin is an injection prepared from human plasma containing concentrated antibodies that provide short-term protection against hepatitis B virus. Unlike vaccination, HBIG offers passive immunity—immediate protection that lasts weeks to months—making it ideal for urgent post-exposure scenarios where vaccination alone is insufficient.\u003cbr\u003e\u003cbr\u003eHow Does HBIG Work?\u003cbr\u003e\u003cbr\u003eHBIG contains donor-derived antibodies (anti-HBs) that bind to hepatitis B surface antigen and neutralize the virus before infection establishes. This passive transfer of immunity provides a critical window of protection while the immune system develops its own response through vaccination.\u003cbr\u003e\u003cbr\u003ePrimary Clinical Uses\u003cbr\u003e\u003cbr\u003ePost-exposure prophylaxis (PEP) following occupational or accidental contact with HBV-infected blood or body fluids in healthcare and laboratory settings. Prevention of perinatal transmission from HBsAg-positive mothers to newborns—a cornerstone of vertical transmission prevention protocols. Protection of unvaccinated individuals or those with inadequate antibody response to hepatitis B vaccines. Prophylaxis in liver transplant recipients to prevent HBV reinfection.\u003cbr\u003e\u003cbr\u003eDuration \u0026amp; Limitations\u003cbr\u003e\u003cbr\u003eHBIG provides temporary protection only and cannot replace long-term immunity from hepatitis B vaccination. Healthcare providers typically administer HBIG alongside the hepatitis B vaccine series to establish both immediate and lasting protection.\u003cbr\u003e\u003cbr\u003eImportant Safety Information\u003cbr\u003e\u003cbr\u003eContraindicated in patients with hypersensitivity to human immunoglobulin products, IgA deficiency with anti-IgA antibodies, or history of severe systemic reactions to immune globulins. Dosage and administration schedule must be determined by qualified healthcare professionals based on exposure type, patient age, and clinical circumstances. Do not use without medical consultation and proper clinical assessment.\u003cbr\u003e\u003cbr\u003eConsult your healthcare provider for personalized guidance on HBIG administration, vaccination protocols, and post-exposure management.","brand":"3MGS","offers":[{"title":"(100IU\/0.5mL) Solution for IM Injection in 0.5mL Glass Vial 1's","offer_id":48942518206601,"sku":"202405230101","price":4500.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0789\/6550\/6185\/files\/Hepabig6001PPS0_3676fa20-5756-4aba-805e-63892a2b3b03.jpg?v=1794275219","url":"https:\/\/shoplumvella.shop\/products\/hepabig-hepatitis-b-human-immunoglobulin","provider":"Elmwood Trading","version":"1.0","type":"link"}